A Significant Proportion of Small Bowel Obstructions Require >48 Hours to Resolve After Gastrografin

J Surg Res. 2019 Jan:233:408-412. doi: 10.1016/j.jss.2018.08.019. Epub 2018 Sep 18.

Abstract

Background: Gastrografin (GG)-based nonoperative approach is both diagnostic and therapeutic for partial small bowel obstruction (SBO). Absence of X-ray evidence of GG in the colon after 8 h is predictive of the need for operation, and a recent trial used 48 h to prompt operation. We hypothesize that a significant number of patients receiving the GG challenge require >48 h before an effect is seen.

Methods: A post hoc analysis of an Eastern Association for the Surgery of Trauma multi-institutional SBO database was performed including only those receiving GG challenge. Successful nonoperative management (NOM) was defined as passage of flatus or nasogastric tube (NGT) removal. NOM was considered a failure if operative intervention was required. Multiple logistic regression was performed to identify predictors of delayed (>48 h) GG challenge effect and expressed as odds ratios with 95% confidence intervals.

Results: Of 286 patients receiving GG, 208 patients (73%) were successfully managed nonoperatively. A total of 60 (29%) NOM patients had NGT decompression for >48 h (n = 54) or required >48 h to pass flatus (n = 34), with some requiring both (n = 28). Prior abdominal operations and SBO admission were protective of delayed GG effect (0.411 [0.169-1.00], P < 0.05; 0.478 [0.240-0.952], P < 0.036).

Conclusions: A significant proportion of patients at 48 h (29%) "failed" the GG challenge as they had yet to pass flatus or still required NGT but were nonetheless successfully managed nonoperatively. Extending the GG challenge beyond 48 h may help avoid unnecessary operations.

Level of evidence: Level II.

Keywords: Gastrografin; Nonoperative management; Small bowel obstruction.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Conservative Treatment / methods*
  • Contrast Media / administration & dosage*
  • Datasets as Topic
  • Diatrizoate Meglumine / administration & dosage*
  • Female
  • Humans
  • Intestinal Obstruction / diagnostic imaging
  • Intestinal Obstruction / therapy*
  • Intestine, Small / diagnostic imaging
  • Intubation, Gastrointestinal
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Retrospective Studies
  • Time Factors
  • Tissue Adhesions / diagnostic imaging
  • Tissue Adhesions / therapy
  • Treatment Outcome

Substances

  • Contrast Media
  • Diatrizoate Meglumine